Biomedical Occupation or Discipline – Page 28

WuXi AppTec Faces Revenue Decline Amid Looming BIOSECURE Act Threat

12 months ago talkbio0Tagged AppTec, BIOSECURE, Biotechnology, Relations, Revenue Decline, WuXi

WuXi AppTec, BIOSECURE Act, Revenue Decline, Biotechnology, US-China Relations

Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease

12 months ago talkbio0Tagged Biosciences, Crohn 's disease, Drug Development, Failure (biologic function), Inhibitor, Phase 2 Clinical Trials, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure

Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback

12 months ago talkbio0Tagged Arthritis, Psoriatic, Biosciences, Crohn 's disease, Drug Development, Inflammatory disorder, Inhibitor, Phase 2 Failure, Psoriasis, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.

GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines

12 months ago talkbio0Tagged bioplatform companies, Drug Discovery, Flagship, Immunology, Partnership, Pfizer, Pioneering, Respiration Disorders, RNA, Messenger, SmithKline Beecham, Vaccines

GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership

Sun Pharma Secures FDA Approval for Leqselvi, a JAK Inhibitor for Severe Alopecia Areata

12 months ago talkbio0Tagged Alopecia, Approved, Dermatology field, Eli Lilly, Immunology, Inhibitor, Janus kinase, Leqselvi, Pfizer, Sun Pharma, United States Food and Drug Administration

Sun Pharma, Leqselvi, FDA Approval, Alopecia Areata, JAK Inhibitor, Pfizer, Lilly, Immunology, Dermatology

US Government Inks $113 Million Deal with Siga to Enhance Smallpox and Mpox Reserves

12 months ago talkbio0Tagged 3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one, Government, mpox, Procurement, public health medicine (field), Siga

US government, Siga, smallpox, mpox, Tpoxx, procurement deal, public health

FDA Requests Additional Study on AstraZeneca’s Imfinzi for Lung Cancer Treatment

12 months ago talkbio0Tagged AdComm, AstraZeneca, Imfinzi, Malignant neoplasm of lung, Surgery specialty, United States Food and Drug Administration

FDA, AstraZeneca, Imfinzi, Lung Cancer, Surgery, Adcomm

Can Element Biosciences Challenge Illumina in the DNA Sequencing Market?

12 months ago talkbio0Tagged ABC, Anabolism, Avidity Base Chemistry, Aviti sequencer, Biotechnology, Cloudbreak, competition, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Market, SBS, Sequence Analysis

Element Biosciences, Illumina, DNA sequencing, next-generation sequencing (NGS), Avidity Base Chemistry (ABC), sequencing by synthesis (SBS), Cloudbreak, Aviti sequencer, genomics, biotechnology, market competition

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

1 year ago talkbio0Tagged AMT-130, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, neurofilament protein L, NfL, Phase I/II trials, Regenerative Medicine, RMAT, Unified - Type of Agreement, UniQure

uniQure, Huntington’s disease, AMT-130, gene therapy, Phase I/II trials, disease progression, neurofilament light protein (NfL), Unified Huntington’s Disease Rating Scale (cUHDRS), Regenerative Medicine Advanced Therapy (RMAT) designation

Beacon Therapeutics Raises $170 Million to Advance Ocular Gene Therapy

1 year ago talkbio0Tagged AGTC-501, Beacon, Infrequent, J&J, ocular gene therapy, Ophthalmology specialty, Series B financing

Beacon Therapeutics, ocular gene therapy, J&J, Series B financing, AGTC-501, rare ophthalmology